Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EBITDA (2016 - 2025)

Historic EBITDA for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.2 million.

  • Rocket Pharmaceuticals' EBITDA rose 2474.22% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 851.46%. This contributed to the annual value of -$273.2 million for FY2024, which is 521.68% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its EBITDA stood at -$52.2 million for Q3 2025, which was up 2474.22% from -$71.1 million recorded in Q2 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' EBITDA peaked at -$34.0 million during Q2 2021, and registered a low of -$73.7 million during Q2 2024.
  • Its 5-year average for EBITDA is -$58.5 million, with a median of -$62.7 million in 2024.
  • Over the last 5 years, Rocket Pharmaceuticals' EBITDA had its largest YoY gain of 2516.0% in 2021, and its largest YoY loss of 8127.58% in 2021.
  • Rocket Pharmaceuticals' EBITDA (Quarter) stood at -$44.3 million in 2021, then tumbled by 55.83% to -$69.1 million in 2022, then rose by 8.4% to -$63.3 million in 2023, then rose by 0.92% to -$62.7 million in 2024, then rose by 16.66% to -$52.2 million in 2025.
  • Its EBITDA was -$52.2 million in Q3 2025, compared to -$71.1 million in Q2 2025 and -$64.4 million in Q1 2025.